{
  "id": "60258edd1cb411341a0000a9",
  "type": "factoid",
  "question": "What is the primary indication of tocilizumab?",
  "ideal_answer": "Tocilizumab is considered first-line treatment for rheumatoid arthritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31859424"
  ],
  "snippets": [
    {
      "text": "For the first-line bDMARD/tsDMARD, either tumor necrosis factor inhibitors (TNFi), non-TNFi (abatacept, tocilizumab, rituximab), or tsDMARDs, may be considered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31859424",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Approximately 30% of patients with rheumatoid arthritis (RA) respond inadequately to conventional-synthetic disease-modifying anti-rheumatic drugs (csDMARDs). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31859424",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Rheumatoid arthritis"
}